BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 23518403)

  • 1. Modulation of drug-resistant membrane and apoptosis proteins of breast cancer stem cells by targeting berberine liposomes.
    Ma X; Zhou J; Zhang CX; Li XY; Li N; Ju RJ; Shi JF; Sun MG; Zhao WY; Mu LM; Yan Y; Lu WL
    Biomaterials; 2013 Jun; 34(18):4452-65. PubMed ID: 23518403
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mitochondrial targeting liposomes incorporating daunorubicin and quinacrine for treatment of relapsed breast cancer arising from cancer stem cells.
    Zhang L; Yao HJ; Yu Y; Zhang Y; Li RJ; Ju RJ; Wang XX; Sun MG; Shi JF; Lu WL
    Biomaterials; 2012 Jan; 33(2):565-82. PubMed ID: 21983136
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of targeting lonidamine liposomes that circumvent drug-resistant cancer by acting on mitochondrial signaling pathways.
    Li N; Zhang CX; Wang XX; Zhang L; Ma X; Zhou J; Ju RJ; Li XY; Zhao WY; Lu WL
    Biomaterials; 2013 Apr; 34(13):3366-80. PubMed ID: 23410681
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mitochondrial targeting topotecan-loaded liposomes for treating drug-resistant breast cancer and inhibiting invasive metastases of melanoma.
    Yu Y; Wang ZH; Zhang L; Yao HJ; Zhang Y; Li RJ; Ju RJ; Wang XX; Zhou J; Li N; Lu WL
    Biomaterials; 2012 Feb; 33(6):1808-20. PubMed ID: 22136714
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Caveolin-1 mediates chemoresistance in breast cancer stem cells via β-catenin/ABCG2 signaling pathway.
    Wang Z; Wang N; Li W; Liu P; Chen Q; Situ H; Zhong S; Guo L; Lin Y; Shen J; Chen J
    Carcinogenesis; 2014 Oct; 35(10):2346-56. PubMed ID: 25085904
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dietary compound isoliquiritigenin targets GRP78 to chemosensitize breast cancer stem cells via β-catenin/ABCG2 signaling.
    Wang N; Wang Z; Peng C; You J; Shen J; Han S; Chen J
    Carcinogenesis; 2014 Nov; 35(11):2544-54. PubMed ID: 25194164
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The anticancer efficacy of paclitaxel liposomes modified with mitochondrial targeting conjugate in resistant lung cancer.
    Zhou J; Zhao WY; Ma X; Ju RJ; Li XY; Li N; Sun MG; Shi JF; Zhang CX; Lu WL
    Biomaterials; 2013 May; 34(14):3626-38. PubMed ID: 23422592
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The efficacy of WGA modified daunorubicin anti-resistant liposomes in treatment of drug-resistant MCF-7 breast cancer.
    Liu S; Song XL; Wang YH; Wang XM; Xiao Y; Wang X; Cheng L; Li XT
    J Drug Target; 2017 Jul; 25(6):541-553. PubMed ID: 28277825
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High mitochondrial mass identifies a sub-population of stem-like cancer cells that are chemo-resistant.
    Farnie G; Sotgia F; Lisanti MP
    Oncotarget; 2015 Oct; 6(31):30472-86. PubMed ID: 26421710
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sabutoclax, pan-active BCL-2 protein family antagonist, overcomes drug resistance and eliminates cancer stem cells in breast cancer.
    Hu Y; Yagüe E; Zhao J; Wang L; Bai J; Yang Q; Pan T; Zhao H; Liu J; Zhang J
    Cancer Lett; 2018 Jun; 423():47-59. PubMed ID: 29496539
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Berberine and Evodiamine Act Synergistically Against Human Breast Cancer MCF-7 Cells by Inducing Cell Cycle Arrest and Apoptosis.
    Du J; Sun Y; Lu YY; Lau E; Zhao M; Zhou QM; Su SB
    Anticancer Res; 2017 Nov; 37(11):6141-6151. PubMed ID: 29061795
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mithramycin A sensitizes therapy-resistant breast cancer stem cells toward genotoxic drug doxorubicin.
    Saha S; Mukherjee S; Mazumdar M; Manna A; Khan P; Adhikary A; Kajal K; Jana D; Sa G; Mukherjee S; Sarkar DK; Das T
    Transl Res; 2015 May; 165(5):558-77. PubMed ID: 25468484
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ShRNA targeting Notch1 sensitizes breast cancer stem cell to paclitaxel.
    Mao J; Song B; Shi Y; Wang B; Fan S; Yu X; Tang J; Li L
    Int J Biochem Cell Biol; 2013 Jun; 45(6):1064-73. PubMed ID: 23500524
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Folate-mediated mitochondrial targeting with doxorubicin-polyrotaxane nanoparticles overcomes multidrug resistance.
    Wang H; Yin H; Yan F; Sun M; Du L; Peng W; Li Q; Feng Y; Zhou Y
    Oncotarget; 2015 Feb; 6(5):2827-42. PubMed ID: 25605018
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumor-associated macrophages regulate murine breast cancer stem cells through a novel paracrine EGFR/Stat3/Sox-2 signaling pathway.
    Yang J; Liao D; Chen C; Liu Y; Chuang TH; Xiang R; Markowitz D; Reisfeld RA; Luo Y
    Stem Cells; 2013 Feb; 31(2):248-58. PubMed ID: 23169551
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Berberine induces apoptosis in breast cancer cells (MCF-7) through mitochondrial-dependent pathway.
    Patil JB; Kim J; Jayaprakasha GK
    Eur J Pharmacol; 2010 Oct; 645(1-3):70-8. PubMed ID: 20691179
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Combination of Targeted Sunitinib Liposomes and Targeted Vinorelbine Liposomes for Treating Invasive Breast Cancer.
    Shi JF; Sun MG; Li XY; Zhao Y; Ju RJ; Mu LM; Yan Y; Li XT; Zeng F; Lu WL
    J Biomed Nanotechnol; 2015 Sep; 11(9):1568-82. PubMed ID: 26485927
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting therapy with mitosomal daunorubicin plus amlodipine has the potential to circumvent intrinsic resistant breast cancer.
    Zhang Y; Li RJ; Ying X; Tian W; Yao HJ; Men Y; Yu Y; Zhang L; Ju RJ; Wang XX; Zhou J; Chen JX; Li N; Lu WL
    Mol Pharm; 2011 Feb; 8(1):162-75. PubMed ID: 21062083
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Concurrent acetylation of FoxO1/3a and p53 due to sirtuins inhibition elicit Bim/PUMA mediated mitochondrial dysfunction and apoptosis in berberine-treated HepG2 cells.
    Shukla S; Sharma A; Pandey VK; Raisuddin S; Kakkar P
    Toxicol Appl Pharmacol; 2016 Jan; 291():70-83. PubMed ID: 26712469
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination therapy with epigenetic-targeted and chemotherapeutic drugs delivered by nanoparticles to enhance the chemotherapy response and overcome resistance by breast cancer stem cells.
    Li SY; Sun R; Wang HX; Shen S; Liu Y; Du XJ; Zhu YH; Jun W
    J Control Release; 2015 May; 205():7-14. PubMed ID: 25445694
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.